Kamat, Ashish

CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients

Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 549

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 460

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 318

Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita

Teoh, J. Y.-C., Huang, J., Ko, W. Y.-K., Lok, V., Choi, P., Ng, C.-F., Sengupta, S., Mostafid, H., Kamat, A. M., Black, P. C., et al. (2020) · European Urology

Global Cancer Incidence and ScreeningBladder and Urothelial Cancer Treatments

Cited by 257

Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., et al. (2009) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research

Cited by 218

Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.

Jinesh G., G., Chunduru, S., & Kamat, A. M. (2012) · Journal of Leukocyte Biology

Cell death mechanisms and regulationBladder and Urothelial Cancer Treatments

Cited by 60